Table of Contents  
CORRESPONDENCE
Year : 2011  |  Volume : 2  |  Issue : 3  |  Page : 207  

Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis


Department of Pharmacology, VCSG Govt. Medical College, Srikot, Pauri Garhwal, Uttarakhand, India

Date of Web Publication29-Jul-2011

Correspondence Address:
Pinki
Department of Pharmacology, Govt. Medical College, Srikot, Pauri Garhwal, Uttarakhand
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0976-500X.83296

Rights and Permissions

How to cite this article:
Pinki, Thawani V. Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis. J Pharmacol Pharmacother 2011;2:207

How to cite this URL:
Pinki, Thawani V. Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis. J Pharmacol Pharmacother [serial online] 2011 [cited 2019 Jul 21];2:207. Available from: http://www.jpharmacol.com/text.asp?2011/2/3/207/83296

Sir,

We read the article by Sharma S, et al. "Fingolimod (FTY720): First approved oral therapy for multiple sclerosis." [1] It is an innovative treatment for multiple sclerosis developed by Novartis Pharmaceuticals, Switzerland. It is available as once daily oral formulation (capsule form) by the brand name Gileyna. We would like to comment on few points in the article:

The authors have mentioned in the article that Fingolimod sequesters lymphocytes in lymphnodes away from CNS; they have not mentioned their functional ability afterward. It has been found that lymphocytes remain functional and may still be activated within lymphnodes as a part of the immune system. [2]

The authors have mentioned that in the FREEDOMS trial, 1272 patients with relapsing-remitting MS were taken, but it has been found that 2000 patients were taken for the study. [3] The authors have mentioned that two deaths were seen during the TRANSFORMS study, both of which were in the group receiving Fingolimod. But it is unclear whether the drug was responsible for the events. [4]

 
   References Top

1.Sharma S, Mathur AG, Pradhan S, Singh DB, Gupta S. Fingolimod (FTY720): First approved oral therapy for multiple sclerosis. J.Pharmacol Pharmacother 2011; 2: 49 -51.  Back to cited text no. 1
    
2.Available from:http://www.mymultiplesclerosis.co.uk/fingolimod.html [Last accessed on 2011Mar].  Back to cited text no. 2
    
3.Available from: http://www.drugdevelopment-technology.com/projects/fingolimod/ [Last accessed on 2011Apr]   Back to cited text no. 3
    
4.Available from: http://www.msrc.co.uk/index.cfm/fuseaction/show/pageid/1309 [Last accessed on 2011Mar].  Back to cited text no. 4
    




 

Top
  
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed1542    
    Printed91    
    Emailed0    
    PDF Downloaded530    
    Comments [Add]    

Recommend this journal